The review presents an analysis of experimental data on the study of the neurobiological effects of astragaloside IV, which can be used in the treatment of Alzheimer's disease. Astragaloside IV is a cycloartan triterpene saponin, which is found in the roots of membranous milk vetch ( (Fisch. ex Link) Bunge) and has a very wide range of pharmacological activity. In recent years, this compound has attracted attention due to its diverse neurobiological effects. Studies have shown the ability of astragaloside IV to modulate microglial activity. The protective effect of this saponin on neurons from the effects of glutamate-induced neurotoxicity has been demonstrated. In PC12 cells, astragaloside IV is shown to be able to resolve various types of mitochondrial dysfunction and inhibit endoplasmic reticulum stress. This compound is also a PPARγ agonist. experiments have shown that the test substance effectively protects synapses as well as improves cognitive functions, including memory and learning. It is concluded that astragaloside IV, apparently, may be used in the future as a multi-purpose complex therapy for Alzheimer's disease.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.17116/jnevro20251250217 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
"It's almost like not existing": Adult children's experiences of not being recognized and their perceptions of being forgotten by their parents with dementia.
Dementia (London)
March 2025
Department of Educational Psychology, The University of Texas at Austin, USA.
Parents living with dementia sometimes do not recognize their adult child caregivers, who may then perceive they are forgotten. Yet, research on the experience of being unrecognized and perceived as forgotten by a parent with dementia is scarce. Object relations theory suggests healthy development of a child's sense of self during early development is linked to being held in mind by a primary caretaker.
View Article and Find Full Text PDFAge-Related Neurodegenerative Diseases: A Stem Cell's Perspective.
Cells
February 2025
Department of Biochemistry and Molecular Biology and Physiology, Faculty of Medicine, University of Valladolid, 47005 Valladolid, Spain.
Neurodegenerative diseases encompass a number of very heterogeneous disorders, primarily characterized by neuronal loss and a concomitant decline in neurological function. Examples of this type of clinical condition are Alzheimer's Disease, Parkinson's Disease, Huntington's Disease and Amyotrophic Lateral Sclerosis. Age has been identified as a major risk in the etiology of these disorders, which explains their increased incidence in developed countries.
View Article and Find Full Text PDFThe Role of Perineuronal Nets in Physiology and Disease: Insights from Recent Studies.
Cells
February 2025
Institute of Functional and Clinical Anatomy, Friedrich-Alexander-Universität Erlangen-Nürnberg, 91054 Erlangen, Germany.
Perineuronal nets (PNNs) are specialized extracellular matrix structures that predominantly surround inhibitory neurons in the central nervous system (CNS). They have been identified as crucial regulators of synaptic plasticity and neuronal excitability. This literature review aims to summarize the current state of knowledge about PNNs, their molecular composition and structure, as well as their functional roles and involvement in neurological diseases.
View Article and Find Full Text PDFTherapeutics for Dementia and Alzheimer's Disease in Unani Medicine.
Altern Ther Health Med
March 2024
Alzheimer's disease refers to a neurological disorder marked by memory loss and cognitive dysfunction caused by the death of brain cells. It is a progressive, devitalizing disease of aging that has skyrocketed in recent years. The disease progresses gradually, with symptoms including forgetfulness, difficulty with language or communication, disorientation, mood swings, and changes in behaviour.
View Article and Find Full Text PDFUse of Safety Net Enclosures as an Additional Treatment of Neuropsychiatric Symptoms in Dementia: A Prospective Cohort Study.
Alzheimer Dis Assoc Disord
March 2025
Parnassia Psychiatric Institute, Den Haag, The Netherlands.
Objective: Safety net enclosures are used in addition to (non-) pharmacological interventions in patients suffering from neuropsychiatric symptoms in dementia. However, no data on effectiveness are available.
Methods: In a prospective observational cohort study of 81 patients diagnosed with dementia, and admitted to a geriatric ward of a psychiatric hospital, available behavioral assessment scores were used to compare 45 patients who used safety net enclosures with 36 patients who never used safety net enclosures.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!